A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Status:
Recruiting
Trial end date:
2024-05-28
Target enrollment:
Participant gender:
Summary
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and
Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY®
Injection in Healthy Chinese Male Subjects